Sun Pharma
Ad
related to: dr reddy pharmaceuticals- Wet AMD Safety Data
Explore Safety Data & Information
Designed For HCPs.
- Multiple Indications
Learn About A Treatment Option For
Wet AMD, DME, DR, and MEfRVO.
- Safety Profile For MEfRVO
Discover The Safety Profile For
This MEfRVO Treatment Option.
- DME Dosing Administration
Find Dosing Information
Information For HCPs.
- DR Dosing Information
Find Dosing & Administration Info
For Diabetic Retinopathy Treatment.
- Resource Center
Visit The Resource Center For The
Info You & Your Patients May Need.
- Wet AMD Safety Data
Search results
Results from the WOW.Com Content Network
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas.
G. V. Prasad (son-in-law) Kallam Anji Reddy (10 August 1941 – 15 March 2013) was an Indian entrepreneur in the pharmaceutical industry, the founder-chairman of Dr. Reddy's Laboratories, which he established in 1984, and chairman of Dr Reddy's Foundation (DRF), the corporate social responsibility arm of the group, established 1996.
It then acquired a respiratory treatment product, and an infant skincare brand from Dr. Reddy's Laboratories. It also bought a majority stake in the Ayurvedic and herbal products manufacturer, Upakarma Ayurveda. In 2022, the company entered agritech and pet care segments.
Dr. Reddy's Laboratories (NYS: RDY) reported earnings on May 11.Here are the numbers you need to know. The 10-second takeaway For the quarter ended March 31 (Q4), Dr. Reddy's Laboratories beat ...
Kallam Satish Reddy is an Indian business executive and current Chairman of Dr. Reddy's Laboratories. [2] [3] Reddy joined Dr. Reddy's Laboratories in 1993 as executive director. Elevated to the role of Managing Director in 1997, he led the company's transition from a manufacturer of active pharmaceutical ingredients to one with a diverse ...
Jeffrey Aubé. Dumbala Srinivasa Reddy (born 1971) is currently Director CSIR-IICT Indian Institute of Chemical Technology [1] Hyderabad India (June 2022), he has additional charge of CSIR-IIIM CSIR-Institute of Integrative Medicine [2] at Jammu and CSIR-CDRI CSIR-Drug Research Institute [3] at Lucknow, India. CSIR-IICT Hyderabad India.
He is widely credited [by whom?] as the architect of Dr. Reddy's successful global generics strategy. He envisioned newer business platforms like the Custom Pharmaceutical business and Specialty pharmaceuticals and is dedicated to building the innovation side of the business.
In June 2016 Indian pharmaceutical company Dr. Reddy's Laboratories Ltd bought 8 (ANDA) Abbreviated New Drug Applications for $350 million in cash. Also in June 2016 Teva sold two ANDAs to Indian pharmaceutical company Zydus Cadilla, strengthening its US portfolio.
Wockhardt is an Indian pharmaceutical and biotechnology company headquartered in Mumbai, India. It produces formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs). The company has manufacturing plants in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France.
Ranbaxy competed with the maker of brand-name Zocor, Merck & Co.; IVAX Corporation (which was acquired by and merged into Teva Pharmaceutical Industries Ltd.), which has 180-day exclusivity at strengths other than 80 mg; and Dr. Reddy's Laboratories and India, whose authorized generic version (licensed by Merck) is exempt from exclusivity.